Revised adult T-cell leukemia-lymphoma international consensus meeting report

Lucy B. Cook, Shigeo Fuji, Olivier Hermine, Ali Bazarbachi, Juan Carlos Ramos, Lee Ratner, Steve Horwitz, Paul Fields, Alina Tanase, Horia Bumbea, Kate Cwynarski, Graham Taylor, Thomas A. Waldmann, Achilea Bittencourt, Ambroise Marcais, Felipe Suarez, David Sibon, Adrienne Phillips, Matthew Lunning, Reza FaridYoshitaka Imaizumi, Ilseung Choi, Takashi Ishida, Kenji Ishitsuka, Takuya Fukushima, Kaoru Uchimaru, Akifumi Takaori-Kondo, Yoshiki Tokura, Atae Utsunomiya, Masao Matsuoka, Kunihiro Tsukasaki, Toshiki Watanabe

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

PURPOSE Adult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy caused by chronic infection with human T-lymphotropic virus type 1 with diverse clinical features and prognosis. ATL remains a challenging disease as a result of its diverse clinical features, multidrug resistance of malignant cells, frequent large tumor burden, hypercalcemia, and/or frequent opportunistic infection. In 2009, we published a consensus report to define prognostic factors, clinical subclassifications, treatment strategies, and response criteria. The 2009 consensus report has become the standard reference for clinical trials in ATL and a guide for clinical management. Since the last consensus there has been progress in the understanding of the molecular pathophysiology of ATL and risk-adapted treatment approaches. METHODS Reflecting these advances, ATL researchers and clinicians joined together at the 18th International Conference on Human Retrovirology—Human T-Lymphotropic Virus and Related Retroviruses—in Tokyo, Japan, March, 2017, to review evidence for current clinical practice and to update the consensus with a new focus on the subtype classification of cutaneous ATL, CNS lesions in aggressive ATL, management of elderly or transplantation-ineligible patients, and treatment strategies that incorporate up-front allogeneic hematopoietic stem-cell transplantation and novel agents. RESULTS As a result of lower-quality clinical evidence, a best practice approach was adopted and consensus statements agreed on by coauthors (. 90% agreement). CONCLUSION This expert consensus highlights the need for additional clinical trials to develop novel standard therapies for the treatment of ATL

Original languageEnglish (US)
Pages (from-to)677-687
Number of pages11
JournalJournal of Clinical Oncology
Volume37
Issue number8
DOIs
StatePublished - Mar 10 2019

Fingerprint

Adult T Cell Leukemia Lymphoma
Clinical Trials
Therapeutics
Human T-lymphotropic virus 1
Tokyo
Hematopoietic Stem Cell Transplantation
Opportunistic Infections
Hypercalcemia
Multiple Drug Resistance
Tumor Burden
Practice Guidelines
Japan
Transplantation
Research Personnel
Viruses
T-Lymphocytes
Skin
Infection

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cook, L. B., Fuji, S., Hermine, O., Bazarbachi, A., Ramos, J. C., Ratner, L., ... Watanabe, T. (2019). Revised adult T-cell leukemia-lymphoma international consensus meeting report. Journal of Clinical Oncology, 37(8), 677-687. https://doi.org/10.1200/JCO.18.00501

Revised adult T-cell leukemia-lymphoma international consensus meeting report. / Cook, Lucy B.; Fuji, Shigeo; Hermine, Olivier; Bazarbachi, Ali; Ramos, Juan Carlos; Ratner, Lee; Horwitz, Steve; Fields, Paul; Tanase, Alina; Bumbea, Horia; Cwynarski, Kate; Taylor, Graham; Waldmann, Thomas A.; Bittencourt, Achilea; Marcais, Ambroise; Suarez, Felipe; Sibon, David; Phillips, Adrienne; Lunning, Matthew; Farid, Reza; Imaizumi, Yoshitaka; Choi, Ilseung; Ishida, Takashi; Ishitsuka, Kenji; Fukushima, Takuya; Uchimaru, Kaoru; Takaori-Kondo, Akifumi; Tokura, Yoshiki; Utsunomiya, Atae; Matsuoka, Masao; Tsukasaki, Kunihiro; Watanabe, Toshiki.

In: Journal of Clinical Oncology, Vol. 37, No. 8, 10.03.2019, p. 677-687.

Research output: Contribution to journalArticle

Cook, LB, Fuji, S, Hermine, O, Bazarbachi, A, Ramos, JC, Ratner, L, Horwitz, S, Fields, P, Tanase, A, Bumbea, H, Cwynarski, K, Taylor, G, Waldmann, TA, Bittencourt, A, Marcais, A, Suarez, F, Sibon, D, Phillips, A, Lunning, M, Farid, R, Imaizumi, Y, Choi, I, Ishida, T, Ishitsuka, K, Fukushima, T, Uchimaru, K, Takaori-Kondo, A, Tokura, Y, Utsunomiya, A, Matsuoka, M, Tsukasaki, K & Watanabe, T 2019, 'Revised adult T-cell leukemia-lymphoma international consensus meeting report', Journal of Clinical Oncology, vol. 37, no. 8, pp. 677-687. https://doi.org/10.1200/JCO.18.00501
Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L et al. Revised adult T-cell leukemia-lymphoma international consensus meeting report. Journal of Clinical Oncology. 2019 Mar 10;37(8):677-687. https://doi.org/10.1200/JCO.18.00501
Cook, Lucy B. ; Fuji, Shigeo ; Hermine, Olivier ; Bazarbachi, Ali ; Ramos, Juan Carlos ; Ratner, Lee ; Horwitz, Steve ; Fields, Paul ; Tanase, Alina ; Bumbea, Horia ; Cwynarski, Kate ; Taylor, Graham ; Waldmann, Thomas A. ; Bittencourt, Achilea ; Marcais, Ambroise ; Suarez, Felipe ; Sibon, David ; Phillips, Adrienne ; Lunning, Matthew ; Farid, Reza ; Imaizumi, Yoshitaka ; Choi, Ilseung ; Ishida, Takashi ; Ishitsuka, Kenji ; Fukushima, Takuya ; Uchimaru, Kaoru ; Takaori-Kondo, Akifumi ; Tokura, Yoshiki ; Utsunomiya, Atae ; Matsuoka, Masao ; Tsukasaki, Kunihiro ; Watanabe, Toshiki. / Revised adult T-cell leukemia-lymphoma international consensus meeting report. In: Journal of Clinical Oncology. 2019 ; Vol. 37, No. 8. pp. 677-687.
@article{88a84afdf8554236b83869c6670e44bb,
title = "Revised adult T-cell leukemia-lymphoma international consensus meeting report",
abstract = "PURPOSE Adult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy caused by chronic infection with human T-lymphotropic virus type 1 with diverse clinical features and prognosis. ATL remains a challenging disease as a result of its diverse clinical features, multidrug resistance of malignant cells, frequent large tumor burden, hypercalcemia, and/or frequent opportunistic infection. In 2009, we published a consensus report to define prognostic factors, clinical subclassifications, treatment strategies, and response criteria. The 2009 consensus report has become the standard reference for clinical trials in ATL and a guide for clinical management. Since the last consensus there has been progress in the understanding of the molecular pathophysiology of ATL and risk-adapted treatment approaches. METHODS Reflecting these advances, ATL researchers and clinicians joined together at the 18th International Conference on Human Retrovirology—Human T-Lymphotropic Virus and Related Retroviruses—in Tokyo, Japan, March, 2017, to review evidence for current clinical practice and to update the consensus with a new focus on the subtype classification of cutaneous ATL, CNS lesions in aggressive ATL, management of elderly or transplantation-ineligible patients, and treatment strategies that incorporate up-front allogeneic hematopoietic stem-cell transplantation and novel agents. RESULTS As a result of lower-quality clinical evidence, a best practice approach was adopted and consensus statements agreed on by coauthors (. 90{\%} agreement). CONCLUSION This expert consensus highlights the need for additional clinical trials to develop novel standard therapies for the treatment of ATL",
author = "Cook, {Lucy B.} and Shigeo Fuji and Olivier Hermine and Ali Bazarbachi and Ramos, {Juan Carlos} and Lee Ratner and Steve Horwitz and Paul Fields and Alina Tanase and Horia Bumbea and Kate Cwynarski and Graham Taylor and Waldmann, {Thomas A.} and Achilea Bittencourt and Ambroise Marcais and Felipe Suarez and David Sibon and Adrienne Phillips and Matthew Lunning and Reza Farid and Yoshitaka Imaizumi and Ilseung Choi and Takashi Ishida and Kenji Ishitsuka and Takuya Fukushima and Kaoru Uchimaru and Akifumi Takaori-Kondo and Yoshiki Tokura and Atae Utsunomiya and Masao Matsuoka and Kunihiro Tsukasaki and Toshiki Watanabe",
year = "2019",
month = "3",
day = "10",
doi = "10.1200/JCO.18.00501",
language = "English (US)",
volume = "37",
pages = "677--687",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Revised adult T-cell leukemia-lymphoma international consensus meeting report

AU - Cook, Lucy B.

AU - Fuji, Shigeo

AU - Hermine, Olivier

AU - Bazarbachi, Ali

AU - Ramos, Juan Carlos

AU - Ratner, Lee

AU - Horwitz, Steve

AU - Fields, Paul

AU - Tanase, Alina

AU - Bumbea, Horia

AU - Cwynarski, Kate

AU - Taylor, Graham

AU - Waldmann, Thomas A.

AU - Bittencourt, Achilea

AU - Marcais, Ambroise

AU - Suarez, Felipe

AU - Sibon, David

AU - Phillips, Adrienne

AU - Lunning, Matthew

AU - Farid, Reza

AU - Imaizumi, Yoshitaka

AU - Choi, Ilseung

AU - Ishida, Takashi

AU - Ishitsuka, Kenji

AU - Fukushima, Takuya

AU - Uchimaru, Kaoru

AU - Takaori-Kondo, Akifumi

AU - Tokura, Yoshiki

AU - Utsunomiya, Atae

AU - Matsuoka, Masao

AU - Tsukasaki, Kunihiro

AU - Watanabe, Toshiki

PY - 2019/3/10

Y1 - 2019/3/10

N2 - PURPOSE Adult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy caused by chronic infection with human T-lymphotropic virus type 1 with diverse clinical features and prognosis. ATL remains a challenging disease as a result of its diverse clinical features, multidrug resistance of malignant cells, frequent large tumor burden, hypercalcemia, and/or frequent opportunistic infection. In 2009, we published a consensus report to define prognostic factors, clinical subclassifications, treatment strategies, and response criteria. The 2009 consensus report has become the standard reference for clinical trials in ATL and a guide for clinical management. Since the last consensus there has been progress in the understanding of the molecular pathophysiology of ATL and risk-adapted treatment approaches. METHODS Reflecting these advances, ATL researchers and clinicians joined together at the 18th International Conference on Human Retrovirology—Human T-Lymphotropic Virus and Related Retroviruses—in Tokyo, Japan, March, 2017, to review evidence for current clinical practice and to update the consensus with a new focus on the subtype classification of cutaneous ATL, CNS lesions in aggressive ATL, management of elderly or transplantation-ineligible patients, and treatment strategies that incorporate up-front allogeneic hematopoietic stem-cell transplantation and novel agents. RESULTS As a result of lower-quality clinical evidence, a best practice approach was adopted and consensus statements agreed on by coauthors (. 90% agreement). CONCLUSION This expert consensus highlights the need for additional clinical trials to develop novel standard therapies for the treatment of ATL

AB - PURPOSE Adult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy caused by chronic infection with human T-lymphotropic virus type 1 with diverse clinical features and prognosis. ATL remains a challenging disease as a result of its diverse clinical features, multidrug resistance of malignant cells, frequent large tumor burden, hypercalcemia, and/or frequent opportunistic infection. In 2009, we published a consensus report to define prognostic factors, clinical subclassifications, treatment strategies, and response criteria. The 2009 consensus report has become the standard reference for clinical trials in ATL and a guide for clinical management. Since the last consensus there has been progress in the understanding of the molecular pathophysiology of ATL and risk-adapted treatment approaches. METHODS Reflecting these advances, ATL researchers and clinicians joined together at the 18th International Conference on Human Retrovirology—Human T-Lymphotropic Virus and Related Retroviruses—in Tokyo, Japan, March, 2017, to review evidence for current clinical practice and to update the consensus with a new focus on the subtype classification of cutaneous ATL, CNS lesions in aggressive ATL, management of elderly or transplantation-ineligible patients, and treatment strategies that incorporate up-front allogeneic hematopoietic stem-cell transplantation and novel agents. RESULTS As a result of lower-quality clinical evidence, a best practice approach was adopted and consensus statements agreed on by coauthors (. 90% agreement). CONCLUSION This expert consensus highlights the need for additional clinical trials to develop novel standard therapies for the treatment of ATL

UR - http://www.scopus.com/inward/record.url?scp=85062623443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062623443&partnerID=8YFLogxK

U2 - 10.1200/JCO.18.00501

DO - 10.1200/JCO.18.00501

M3 - Article

C2 - 30657736

AN - SCOPUS:85062623443

VL - 37

SP - 677

EP - 687

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -